Insurance Coverage for Ketamine Therapy in Canada

Ketamine therapy in Canada costs CAD $375–$1,400+ per session and a 6-session course can run CAD $2,250–$8,400 out-of-pocket. Whether any of that cost is covered depends on the form of ketamine, your province, your employer plan, and whether you qualify for workers' compensation or veterans' benefits. Coverage exists — but it's fragmented. This guide maps every Canadian pathway: provincial public plans, the major private group benefit carriers, workers' compensation boards, federal programs, and the tax relief available when insurance falls short.

Key takeaways

• Provincial health plans (OHIP, MSP, AHCIP, RAMQ, others) do not cover ketamine for psychiatric indications. Exceptions: Edmonton's Misericordia/Grey Nuns hospital program (AHCIP); Vancouver Coastal Health UBC Hospital program (MSP); QEII Halifax; Yukon covers Spravato.
• Alberta Blue Cross became the first Canadian insurer to cover psychedelic-assisted therapy including ketamine in March 2024.
• Spravato (intranasal esketamine) is the form most likely to be covered by private insurers with prior authorization (Canada Life, Sun Life, Manulife, Green Shield).
• WCB Alberta and WSIB Ontario cover IV ketamine and Spravato for compensable injuries with prior authorization.
• Veterans Affairs Canada covers ketamine non-formulary for service-related TRD or chronic pain — 433 veterans averaged CAD $10,109 in coverage in FY2024–25.
• The federal Medical Expense Tax Credit (METC) and Health Care Spending Accounts (HSA) provide partial recovery of out-of-pocket costs.

The regulatory foundation: why coverage is fragmented

Two regulatory facts shape Canadian insurance coverage for ketamine therapy.

Fact 1: Spravato is approved; generic ketamine for psychiatric use is off-label. Health Canada issued a Notice of Compliance for Spravato (intranasal esketamine) in May 2020, specifically for treatment-resistant MDD in combination with an oral antidepressant. Generic racemic ketamine — IV, IM, sublingual, oral — has no Health Canada psychiatric approval; it is prescribed off-label by physicians, a legal and common practice in Canadian medicine, but one that complicates insurance coverage.

Fact 2: CDA-AMC issued a "Do Not Reimburse" recommendation for Spravato in December 2020. Canada's Drug Agency (formerly CADTH) reviewed esketamine and recommended against public formulary listing, citing uncertainty about which patients would benefit and the cost relative to alternatives. Provinces adopted this recommendation; Spravato does not appear on standard provincial drug formularies as a result. Some private insurers cover Spravato anyway through prior authorization pathways. See the CDA-AMC esketamine review.

The practical consequence: most Canadians pay out-of-pocket for ketamine therapy. The insurance pathways that do exist are insurer-specific, condition-specific, and often require physician-led prior authorization.

Provincial public plan coverage

Public hospital programs are the meaningful exception. If you have severe TRD, a psychiatrist, and access to one of:

• Misericordia or Grey Nuns Hospitals, Edmonton (Covenant Health)
• UBC Hospital Ketamine Intervention Program (VCH)
• QEII Health Sciences Centre, Halifax

…the public pathway is your most cost-effective access route. All three require psychiatrist referral and have eligibility criteria centred on documented antidepressant failures.

Alberta Blue Cross — the Canadian insurance landmark

In March 2024, Alberta Blue Cross became the first Canadian insurer to formally cover psychedelic-assisted therapy, including ketamine-assisted therapy. Coverage applies to eligible group, workplace, and individual plans subject to plan maximums.

Key eligibility criteria:

• Drug must be prescribed by a psychiatrist, or by an appropriately trained physician in consultation with a psychiatrist
• Drug must be dispensed from a licensed pharmacy
• Psychotherapy component delivered only by psychiatrists, clinical psychologists, or regulated healthcare professionals registered with the appropriate Alberta college
• Patient must undergo a comprehensive assessment determining suitability
• Coverage is subject to plan maximums — verify your specific employer plan

Why this matters: Alberta Blue Cross's framework provides a template for coverage criteria that other Canadian insurers may eventually adopt. Many Calgary and Edmonton employers offer Alberta Blue Cross as an employee benefit. For ATMA CENA's full Alberta Blue Cross navigation, see Alberta Blue Cross Coverage for Psychedelic Therapy.

Private group benefit insurers — Spravato pathways

Most private Canadian insurers cover Spravato (esketamine) with prior authorization for documented treatment-resistant MDD. Generic IV/IM ketamine is generally not covered.

Canada Life (employer plans + Public Service Health Care Plan)

Canada Life administers both private employer plans and the federal PSHCP. Spravato is on the prior authorization drug list for both.

• Employer plan PA form: M6453 — canadalife.com Spravato M6453
• PSHCP form: M7520 — welcome.canadalife.com Spravato M7520

Typical criteria: confirmed TRD diagnosis, documented failure of two adequate antidepressant trials, Spravato to be administered alongside an oral SSRI or SNRI under direct healthcare supervision. PSHCP reimburses prescription drugs at 80% of the lowest-priced generic alternative as of January 2024.

Sun Life

Sun Life lists Spravato on its prior authorization drug list (sunlife.ca PA forms). Coverage depends on the specific employer plan; the PA form is submitted by the prescribing physician. IV ketamine is not covered.

Manulife

Manulife covers Spravato through its Specialty Drug Care Program with prior authorization (Manulife Specialty Drug Care). Standard criteria: documented TRD diagnosis, prior antidepressant failure, physician or specialist involvement. Generic ketamine is not on the formulary.

Green Shield Canada

GSC covers Spravato through its Special Authorization process (GreenShield+ prior authorization). The Special Authorization criteria sheet is available through GSC providerConnect for pharmacies. Generic IV ketamine is not covered.

Pacific Blue Cross (BC)

No publicly documented Spravato or ketamine coverage policy as of May 2026. Members should contact Pacific Blue Cross member services (1-888-275-4672) to verify their specific plan.

Medavie Blue Cross (Atlantic Canada + federal veterans)

Through arrangements with Veterans Affairs Canada and CRTCE clinics (Braxia Scientific), Medavie Blue Cross covers ketamine treatments — IV, oral, nasal — at 100% for eligible Canadian Armed Forces and RCMP veterans, plus travel costs. This is veteran-specific coverage, not general Medavie Blue Cross employer plan coverage.

Summary table

Always verify directly with your specific plan administrator before assuming coverage.

Workers' Compensation — the most permissive coverage in Canada

Workers' Compensation Boards in Alberta and Ontario have explicit ketamine coverage for compensable injuries. Other provinces handle case-by-case.

WCB Alberta — most detailed policy

WCB Alberta's procedure manual entry covers IV ketamine and Spravato with prior authorization (Form C1520).

Conditions covered:

• Treatment-resistant major depressive disorder arising from compensable injury
• Complex Regional Pain Syndrome (CRPS)
• Refractory neuropathic pain spreading to larger areas
• Moderate-to-severe MDD (Spravato adjunctive specifically)

Process:

• Form C1520 submitted by treating specialist (neurologist, psychiatrist, physiatrist, or chronic pain specialist)
• WCB medical consultant review
• Initial trial: 6 IV infusions or 4 weeks of Spravato induction
• Continuation reviews every 3 months

For provider WCB pathway support including Form C1520 documentation, see Workers' Compensation Coverage for Psychedelic Therapy in Alberta.

WSIB Ontario — broadest formulary listing

WSIB Ontario listed both ketamine and Spravato in June 2023:

• IV ketamine on 5 formularies: Musculoskeletal (02WS), CNS/PNS (03WS), Psychotraumatic (22WS), Chronic Pain Disability (23WS), Serious Injury (27WS)
• Spravato on 2 formularies: Psychotraumatic (22WS), Serious Injury (27WS)

Conditions: CRPS, refractory neuropathic pain, treatment-resistant depression. Prior authorization required; documented treatment failure of multiple prior medications; pain ratings 4/10+ for pain indications; failure of 2+ oral antidepressants for TRD; appropriate clinical settings (CPSO standards for IV).

WorkSafeBC

Case-by-case review; no formal listing. Multiple evidence-based practice reviews completed; CRPS adjudicated as a separate diagnosis. Workers should request individual case review through their claims manager.

WorkSafeNB

Restrictive case-by-case policy. WorkSafeNB "generally does not recommend" ketamine but may cover in specific compensable major depression cases meeting TRD criteria. Treating providers must complete the Ketamine/Esketamine Review Booklet and obtain pre-approval.

Other provincial WCBs

Saskatchewan, Manitoba, Nova Scotia, PEI, Newfoundland: no published listings. Case-by-case review through claims adjudicator.

Federal programs

Veterans Affairs Canada

VAC covers ketamine as a non-formulary product for service-related TRD or chronic pain. Routes: oral, IV, intranasal (Spravato), and compounded cream.

FY2024–25 data (CBC News, June 2025):

• 433 veterans received reimbursement
• Average reimbursement: CAD $10,109.25 per person

Veterans access through their treating physician submitting a non-formulary authorization request. CRTCE clinics direct-bill via Medavie Blue Cross for eligible veterans. The VAC pathway is one of the more reliable routes to ketamine coverage in Canada for service-connected conditions.

Public Service Health Care Plan (PSHCP)

Federal public servants, retirees, and dependants are covered through PSHCP, administered by Canada Life. Spravato available via PA Form M7520. Drug reimbursement at 80% of the lowest-cost generic alternative since January 2024.

Royal Canadian Mounted Police

RCMP officers may access VAC-equivalent benefits for service-connected conditions. Direct billing at CRTCE clinics through Medavie Blue Cross is available for eligible RCMP veterans.

Indigenous Services Canada — Non-Insured Health Benefits (NIHB)

NIHB provides pharmacy benefits to registered First Nations and recognized Inuit. As of May 2026, no confirmed esketamine or IV ketamine listing has been identified in publicly available NIHB documentation. First Nations and Inuit patients should consult the NIHB Drug Benefit List directly or contact NIHB at 1-800-232-7301.

The tax framework — Medical Expense Tax Credit and HSA

When insurance falls short, the federal METC and Health Care Spending Accounts provide partial recovery.

Medical Expense Tax Credit (METC)

Authority: CRA — Lines 33099 / 33199. Federal credit rate 15% on eligible expenses above the threshold. 2026 threshold: lesser of CAD $2,890 or 3% of net income.

What qualifies for ketamine therapy:

• Physician fees (consultation, prescribing, supervision) — eligible under ITA Section 118.2(2)(a)
• Spravato dispensed by a licensed pharmacy on a physician prescription — eligible under Section 118.2(2)(n)
• Compounded ketamine from a licensed compounding pharmacy on prescription — eligible
• Psychotherapy from a registered psychologist (all provinces) or registered psychotherapist (Ontario) — eligible

Provincial METC rates range from 5.05% (BC, Ontario) to 15% (Quebec). Combined federal + provincial relief on eligible expenses above threshold typically falls between ~19.5% (BC, Ontario) and ~29.5% (Quebec). See TaxTips.ca METC overview for current rates by province.

Example: An Alberta resident earning CAD $80,000 spending CAD $12,000 on uninsured ketamine therapy could see roughly CAD $2,400 in combined federal + provincial tax relief.

Health Care Spending Accounts (HSA)

HSA-eligible expenses track METC eligibility. If an expense qualifies for the METC, it generally qualifies for tax-free HSA reimbursement. HSAs provide dollar-for-dollar tax-free reimbursement, more efficient than the partial METC credit.

Important rule: You cannot double-claim. An expense reimbursed by an HSA cannot also be claimed under METC.

Self-employed and incorporated business owners

Self-employed clinicians and incorporated owners may use Private Health Services Plans (PHSPs) or Corporate HSAs to deduct medical expenses pre-tax. Consult a Canadian tax professional for the right structure for your situation.

How to find out if your plan covers ketamine therapy — 5 steps

Step 1 — Identify which form of ketamine your treatment will use. Spravato is the form most likely to be covered by private insurance. Generic IV/IM ketamine is rarely covered outside Alberta Blue Cross, WCB AB/WSIB ON, and VAC.

Step 2 — Review your benefits booklet or call your plan administrator. Ask specifically: "Is Spravato (esketamine) on the prior authorization drug list?" and "Does my plan have a specialty drug benefit or Health Care Spending Account that could cover ketamine treatment?"

Step 3 — Have your psychiatrist or referring physician submit prior authorization. Insurers require physician or NP submission. Provide your insurance certificate number, group number, and insurer name to the prescribing clinic.

Step 4 — Determine your workers' compensation eligibility. If your condition arose from a workplace injury, file a WCB claim before pursuing private pay. WCB Alberta and WSIB Ontario have explicit policies; other provinces handle case-by-case.

Step 5 — Track expenses for METC and HSA recovery. Keep itemized receipts from every provider — physician, pharmacy (for Spravato), therapy provider. Use any 12-month period ending in the tax year that maximizes your METC claim.

Frequently asked questions

Does insurance cover ketamine therapy in Canada? Provincial public plans do not cover ketamine for psychiatric indications, with limited exceptions (Edmonton hospital program, Vancouver UBC Hospital program, QEII Halifax, Yukon Spravato). Private insurers typically cover Spravato with prior authorization but not generic ketamine. Alberta Blue Cross is the major exception — covering psychedelic-assisted therapy including ketamine for eligible plans since March 2024. WCB Alberta, WSIB Ontario, and Veterans Affairs Canada have specific coverage pathways.

Does OHIP cover ketamine therapy? No. OHIP covers physician consultations but not ketamine drug or administration for psychiatric indications. Spravato is not on the standard ODB formulary; Exceptional Access Program requests are case-by-case.

Does MSP cover ketamine therapy in BC? MSP covers physician consultations and the Vancouver Coastal Health Ketamine Intervention Program at UBC Hospital for eligible TRD patients with psychiatrist referral. Private clinic ketamine is not covered. BC PharmaCare issued a Do Not Reimburse decision for Spravato in August 2021.

Does Alberta Blue Cross cover ketamine therapy? Yes — Alberta Blue Cross covers psychedelic-assisted therapy including ketamine for eligible plans (effective March 2024). Coverage criteria require psychiatrist or physician-with-psychiatrist-consultation prescribing, dispensing from licensed pharmacy, and qualified provider for the psychotherapy component. Plan-specific maximums apply.

Does private insurance cover Spravato in Canada? Most major Canadian private insurers cover Spravato with prior authorization for documented TRD: Canada Life (Forms M6453, M7520), Sun Life, Manulife, Green Shield Canada. Plans differ; verify with your administrator.

Does WCB cover ketamine therapy? WCB Alberta covers IV ketamine and Spravato with prior authorization for compensable TRD, CRPS, and refractory neuropathic pain (Form C1520). WSIB Ontario covers ketamine and Spravato on multiple specialty formularies for compensable injuries. Other provincial WCBs handle case-by-case.

Does Veterans Affairs Canada cover ketamine therapy? Yes. VAC covers ketamine as a non-formulary product for service-related TRD or chronic pain — oral, IV, nasal, or compounded cream. In FY2024–25, 433 veterans received an average of CAD $10,109 in reimbursement.

Can I claim ketamine therapy on my taxes in Canada? Generally yes. Physician-administered ketamine therapy and prescription drugs typically qualify for the Medical Expense Tax Credit (Lines 33099/33199). The threshold is the lesser of 3% of net income or CAD $2,890 (2026). Combined federal + provincial relief on eligible expenses typically runs ~19.5–29.5%.

Is Spravato covered by Health Care Spending Accounts? Yes — HSA-eligible expenses track METC eligibility. If your physician fees and prescription drug costs qualify for METC, they generally qualify for tax-free HSA reimbursement.

What's the difference between coverage for Spravato and generic IV ketamine? Spravato has Health Canada psychiatric approval (TRD) and is more likely to attract private insurance coverage with prior authorization. Generic IV/IM ketamine is off-label and rarely covered by private insurers, with the major exception of Alberta Blue Cross (effective March 2024). The two forms have different regulatory and coverage pathways.

How do I appeal an insurance denial? Insurers have internal appeal processes. Your prescribing physician can submit additional clinical documentation. WCB and VAC denials have provincial/federal appeal pathways. A documented letter from your treating physician outlining medical necessity, prior treatment failures, and supporting peer-reviewed evidence is typically required.

Sources

1. ATMA CENA — Ketamine Therapy Hub: https://psychedelic.healthcare/ketamine-therapy/
2. ATMA CENA — Alberta Blue Cross Coverage: https://psychedelic.healthcare/
3. ATMA CENA — Workers' Compensation Coverage Alberta: https://psychedelic.healthcare/
4. ATMA CENA — Psychedelic-Assisted Therapy: https://psychedelic.healthcare/
5. Health Canada DPD — Spravato (DIN 02499290): https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
6. CDA-AMC — Esketamine Reimbursement Review: https://www.cda-amc.ca/esketamine-hydrochloride
7. CDEC Recommendation — Esketamine: https://www.ncbi.nlm.nih.gov/books/NBK572049/
8. PR Newswire — ATMA CENA Celebrates Alberta Blue Cross Coverage (March 2024): https://www.atmajourney.com/alberta-blue-cross-covers-pat/
9. PsyCan — Alberta Blue Cross Coverage Announcement: https://psychedelicscanada.org/media/2024/04/psycan-welcomes-expansion-of-insurance-coverage-for-psychedelic-assisted-therapy-in-alberta
10. Canada Life — Spravato PA Form M6453 (employer): https://www.canadalife.com/content/dam/canadalife/documents/forms/you-and-your-family/1-0-employer/1-3-request-an-assessment/1-3-2-prior-auth-drugs/en/spravato-m6453.pdf
11. Canada Life — Spravato PA Form M7520 (PSHCP): https://www.welcome.canadalife.com/content/dam/canadalife/documents/forms/you-and-your-family/1-0-employer/1-3-request-an-assessment/1-3-2-prior-auth-drugs/en/pshcp/spravato-m7520.pdf
12. Sun Life — Prior Authorization Drug List: https://www.sunlife.ca/workplace/en/group-benefits/forms/prior-authorization-drug-list-and-forms/
13. Manulife — Specialty Drug Care Program: https://www.manulife.ca/business/news/group-benefits-news/specialty-drug-care-program.html
14. Green Shield Canada — Prior Authorization: https://greenshieldplus.zendesk.com/hc/en-ca/articles/39099095057940-Understanding-prior-authorization
15. WCB Alberta — Ketamine and Esketamine Procedure: https://www.wcb.ab.ca/about-wcb/procedures-manual/pharmaceutical-ketamine-and-esketamine.html
16. WSIB Ontario — Ketamine and Esketamine Formulary Decision (June 2023): https://www.wsib.ca/en/drug-formulary-listing-decision-ketamine-and-esketamine
17. WorkSafeNB — Ketamine Policy: https://www.worksafenb.ca/health-care/treatment-and-recovery/ketamine/
18. WorkSafeBC — IV Ketamine Evidence Review: https://www.worksafebc.com/en/resources/health-care-providers/guides/issues-on-iv-ketamine-and-oral-ketamine-for-chronic-non-cancer-pain-2025-update
19. CBC News — Veterans Ketamine Therapy (June 2025): https://www.cbc.ca/news/canada/newfoundland-labrador/veterans-ketamine-therapy-1.7559186
20. VAC Briefing — Mental Health Treatments (December 2024): https://public.cdn.cloud.veterans.gc.ca/pdf/about-vac/who-we-are/department-officials/minister/briefing/dec2-2024/16-mental-health-treatments-en.pdf
21. CRA — Lines 33099 and 33199 Eligible Medical Expenses: https://www.canada.ca/en/revenue-agency/services/tax/individuals/topics/about-your-tax-return/tax-return/completing-a-tax-return/deductions-credits-expenses/lines-33099-33199-eligible-medical-expenses-you-claim-on-your-tax-return.html
22. CRA RC4065 — Medical Expenses 2025: https://www.canada.ca/en/revenue-agency/services/forms-publications/publications/rc4065/medical-expenses.html
23. TaxTips.ca — Medical Expense Tax Credit: https://www.taxtips.ca/filing/medical-expense-tax-credit.htm
24. BC PharmaCare — Esketamine Decision: https://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/decisions/esketamine_hydrochloride_spravato_dds.pdf
25. Manitoba Enhanced Pharmacare Program: https://www.gov.mb.ca/health/pharmacare/mepp.html
26. Chrenek C, et al. (2024). Edmonton community ketamine program. Front Psychiatry. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1283733/full

Related articles

• Ketamine Therapy in Canada
• Ketamine Therapy Cost in Canada
• How to Qualify for Ketamine Therapy in Canada
• Alberta Blue Cross Coverage for Psychedelic Therapy
• Workers' Compensation Coverage for Psychedelic Therapy in Alberta
• Ketamine Therapy for Depression
• Ketamine Therapy in Calgary
• Ketamine Therapy in Edmonton
• Ketamine Therapy FAQs

Last updated: 2026-05-05